Treatment algorithm, after CAR T-cell therapy management. allo, allogeneic; BR, bendamustine-rituximab; pola, polatuzumab; R-chemo, rituximab plus chemotherapy; tafa + len, tafasitamab plus lenalidomide; tx, treatment.